Pure Global
NCT05905432

Pan-Malaria Transmission-Blocking Vaccine AnAPN1

A Randomized Double-blinded Phase 1 Clinical Trial to Assess Safety, Tolerability and Reactogenicity of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1 in Healthy Adults Living in Gabon
Centre de Recherche Médicale de Lambaréné·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Vaccine AnAPN1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Centre de Recherche Médicale de Lambaréné
Location
Lambaréné, Gabon
Timeline & enrollment
Phase
Phase 1
Start date
Jul 25, 2023
End date
Dec 31, 2023
Enrollment
33 participants
Primary outcome

Adverse events related to the vaccination.

Summary

Malaria is still responsible for more than 627,000 deaths each year, predominantly among
 children under 5 years old. Current reductions in deaths have stagnated, and additional
 setbacks for malaria control programs due to the Coronavirus Disease 2019 (COVID-19) pandemic
 are expected. To achieve malaria elimination and eradication a leverage concerted approaches
 to reduce clinical disease and prevent new infections is a must. The existing malaria
 controls tools including the a recombinant protein-based malaria vaccine (RTS,S ,(trade name
 MosquirixMosquirix )), a malaria vaccine currently undergoing implementation studies and
 endorsed by the World Health Organization on October 7, 2021, can reduce disease burden for
 patients but cannot ultimately support malaria elimination and eradication since their effect
 on malaria transmission is at most partial. Consequently, complementary interventions, such
 as transmission-blocking vaccines (TBVs) may prove to be a cost-effective intervention that
 can reduce on-going residual transmission and the cascade of new infections.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05905432
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05905432 through Pure Global AI's free database. This Phase 1 trial is sponsored by Centre de Recherche Médicale de Lambaréné and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.